Recombinant fibroblast growth factor 4 ameliorates axonal regeneration and functional recovery in acute spinal cord injury through altering microglia/macrophage phenotype
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112188 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Rui Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Orthopaedics/Department of Spine Surgery, Department of Pharmacy and Department of Gastroenterology, Shenzhen Second People's Hospital (Shenzhen Inst…. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Microglia, Macrophages, Nerve Regeneration. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Neuroinflammation is one of the extensive secondary injury processes that aggravate metabolic and cellular dysfunction and tissue loss following spinal cord injury (SCI). Thus, an anti-inflammatory strategy is crucial for modulating structural and functional restoration during the stage of acute and chronic SCI. Recombinant fibroblast growth factor 4 (rFGF4) has eliminated its mitogenic activity and demonstrated a metabolic regulator for alleviating hyperglycemia in type 2 diabetes and liver injury in non-alcoholic steatohepatitis. However, it remains to be explored whether or not rFGF4 has a neuroprotective effect for restoring neurological disorders, such as SCI. Here, we identified that rFGF4 could polarize microglia/macrophages into the restorative M2 subtype, thus exerting an anti-inflammatory effect to promote neurological functional recovery and nerve fiber regeneration after SCI. Importantly, these effects by rFGF4 were related to triggering PI3K/AKT/GSK3β and attenuating TLR4/NF-κB signaling axes. Conversely, gene silencing of the PI3K/AKT/GSK3β signaling or pharmacological reactivation of the TLR4/NF-κB axis aggravated inflammatory reaction. Thus, our findings highlight rFGF4 as a potentially therapeutic regulator for repairing SCI, and its outstanding effect is associated with regulating macrophage/microglial polarization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Orthopaedics/Department of Spine Surgery, Department of Pharmacy and Department of Gastroenterology, Shenzhen Second People's Hospital (Shenzhen Institute of Translational Medicine), Guangdong Key Laboratory for Biomedi…
Zitieren
APA
Li, R., Feng, J., Li, L., Luo, G., Shi, Y., Shen, S., Yuan, X., Wu, J., Yan, B., & Yang, L. (2024). Recombinant fibroblast growth factor 4 ameliorates axonal regeneration and functional recovery in acute spinal cord injury through altering microglia/macrophage phenotype. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112188
Vancouver
Li R, Feng J, Li L, Luo G, Shi Y, Shen S, et al. Recombinant fibroblast growth factor 4 ameliorates axonal regeneration and functional recovery in acute spinal cord injury through altering microglia/macrophage phenotype. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112188
BibTeX
@article{Li2024,
author = {Li, Rui and Feng, Juerong and Li, Liuxun and Luo, Guotian and Shi, Yongpeng and Shen, Shichao and Yuan, Xinrong and Wu, Jianlong and Yan, Bin and Yang, Lei},
title = {Recombinant fibroblast growth factor 4 ameliorates axonal regeneration and functional recovery in acute spinal cord injury through altering microglia/macrophage phenotype},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112188}
}
EUVIMED